Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...
The results confirmed my worst fears: I was a carrier of a BRCA gene mutation. At the age of 25, I found myself sitting in ...
BRCA mutations are inextricably linked with breasts, but they can also lead to cancer in the pancreas, the prostate, and maybe more parts of the body.
Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...